Skip to content

Supplier News

GSK adapts to changing pharmaceutical business model

One of the first big drug makers to hit the so-called patent cliff, GlaxoSmithKline (GSK), has responded to a changing industry business model by rethinking its strategic positioning and adopting a more balanced approach to the evolving health care ­marketplace.

Energizer brands highlight sun protection poll results

The Skin Cancer Foundation, along with Energizer Personal Care’s Banana Boat and Hawaiian Tropic sunscreen brands, has released survey findings showing that men are less knowledgeable about sun protection than women. Energizer said Wednesday that the online poll of 1,000 U.S.

Abreva: Cold sore remedy packaging can be deceiving

Most Americans don’t check ingredients of over-the-counter cold sore medicines and select products based on their packaging, according to a survey by Abreva. The GlaxoSmithKline Consumer Healthcare cold sore treatment brand said Tuesday that its poll of 1,000 U.S.

Vicks unveils ZzzQuil sleeping aid

Venerable cough/cold remedy brand Vicks NyQuil has added a sleep aid to its product lineup. The Procter & Gamble Co. brand said Monday that the new over-the-counter product, ZzzQuil, is designed to provide relief for occasional sleeplessness and is non-habit forming.

TheraPearl teams up with NFL Players Association

Hot and cold therapy product maker TheraPearl has entered a licensing pact with the NFL Players Association (NFLPA) TheraPearl said Friday that its products are designed to aid in post-workout recovery, making them a natural solution for the NFLPA and pro football players everywhere.

Daymon serves up private-brand mobile app

Retail branding specialist Daymon Worldwide has launched what it calls the first mobile application for private brands. The app provides tools and links to information on the private-brand industry.

Settlement clears Perrigo to launch clobetasol foam

Perrigo Co. has settled Hatch-Waxman litigation for its clobetasol propionate emulsion foam 0.05% brought by Stiefel Research Australia Pty. Ltd., a GlaxoSmithKline company. Perrigo said Monday that under the settlement it can launch a generic version of Stiefel’s Olux-E Foam 0.05% on Feb.